CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 157518-157787 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/038354e8830fe01feb621a12e8a8c467a15b6354","sourcedb":"CORD-19","sourceid":"038354e8830fe01feb621a12e8a8c467a15b6354","text":"Currently, pharmaceutical interest in compounds with activity against respiratory viruses is limited because of a focus on chronic disease, unattractive commercial opportunities, and the high standard required to obtain FDA approval for non-life-threatening conditions.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T986","span":{"begin":0,"end":269},"obj":"Sentence"},{"id":"T26792","span":{"begin":0,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T986","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T26792","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T363","span":{"begin":0,"end":269},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T363","pred":"source","obj":"Epistemic_Statements"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T54","span":{"begin":0,"end":269},"obj":"Sentence"}],"attributes":[{"subj":"T54","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#d1ec93","default":true},{"id":"Epistemic_Statements","color":"#ec93eb"},{"id":"CORD-19_Custom_license_subset","color":"#93ecd2"}]}]}}